Last reviewed · How we verify
OsrHSA
OsrHSA is a recombinant human serum albumin fusion protein designed to extend the half-life and improve the pharmacokinetics of a therapeutic payload.
At a glance
| Generic name | OsrHSA |
|---|---|
| Sponsor | Healthgen Biotechnology Corp. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
OsrHSA leverages human serum albumin (HSA) as a carrier platform to enhance drug stability, reduce immunogenicity, and prolong circulating half-life. This approach allows for less frequent dosing and potentially improved therapeutic efficacy by maintaining sustained drug exposure.
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia (PHASE3)
- A Phase II Study of OsrHSA in Patients With Decompensated Cirrhotic Ascites (PHASE2)
- A Study of OsrHSA in Adult Healthy Male and Female Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OsrHSA CI brief — competitive landscape report
- OsrHSA updates RSS · CI watch RSS
- Healthgen Biotechnology Corp. portfolio CI